BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference

04.27.2023

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

04.11.2023

BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb’s OPDIVO® (nivolumab)

03.23.2023

BridgeBio Pharma Shares Preliminary Findings on Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)

03.21.2023

BridgeBio Pharma to Present Preliminary Findings on its Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)

03.17.2023

BridgeBio Pharma Announces Pricing of Public Offering of Common Stock

03.08.2023

BridgeBio Pharma Announces Proposed Public Offering of Common Stock

03.06.2023

BridgeBio Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Events

03.06.2023

BridgeBio to Host Investor Call to Discuss Phase 2 Cohort 5 Data for Achondroplasia on March 6, 2023

03.03.2023

BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update

02.23.2023

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

02.17.2023

BridgeBio Pharma to Host Educational Roundtable with Esteemed Achondroplasia Expert on February 16, 2023

02.13.2023

BridgeBio Pharma to Participate in February and March Investor Events

02.08.2023

BridgeBio Pharma to Present at the J.P. Morgan Healthcare Conference

01.04.2023

BridgeBio Pharma Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1

12.22.2022

BridgeBio Pharma to Participate in November Investor Events

11.09.2022

BridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Update

11.03.2022

BridgeBio Pharma Highlights its RAS Precision Oncology Portfolio and Shares Compelling Data from Next-generation G12C Inhibitor and Novel PI3Kα:RAS Breaker Mechanism at the Fourth RAS Initiative Symposium

10.17.2022

BridgeBio Pharma Presents 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)

10.14.2022

BridgeBio Pharma Presents Updated Positive Data from its BBP-812 Canavan Disease Gene Therapy Program at the 51st Annual Meeting of the Child Neurology Society

10.13.2022

news

Catch up on news from BridgeBio and our pipeline developments. Follow us on LinkedIn, Twitter and Facebook to keep up with all of the latest news.

news archive

icon icon